Sign in
Active, not recruitingPhase 1/2

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

Key facts

Who runs it
Virginia Commonwealth University
Where
Richmond, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
80 people, planned
Started
21 Nov 2022
Expected to end
Nov 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Intestinal Microbiota Transplant (IMT) Capsules
  • Placebo Capsules
Record updated
24 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (30)Hide the full registry criteria

Who can take part

  • ->18 years of age
  • Advanced liver disease
  • Able to give written, informed consent
  • Alcohol as a cause of advanced liver disease
  • Continued sustained drinking
  • Having previously declined a referral to traditional AUD therapy services or having failed such treatments

Who cannot take part

  • Clinically significant use of illicit drugs
  • Adverse event attributable to prior IMT
  • Recent or current alcoholic hepatitis
  • Uncontrolled mood disorders or primary psychotic conditions
  • Unclear diagnosis of chronic liver disease
  • known untreated, in-situ luminal GI cancers
  • chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease)
  • History of aspiration, gastroparesis, intestinal obstruction
  • Severe anaphylactic food allergy
  • acute illness or fever on the day of planned FMT
  • Other conditions which make patients are poor candidate for this study per investigator judgement
  • WBC count<1000
  • allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil)
  • Lack of sustained drinking
  • Alcohol withdrawal symptoms
  • MELD score>17
  • Current hepatic encephalopathy on lactulose and/or rifaximin
  • Non-elective hospitalization within last month
  • on dialysis
  • Dysphagia within 2 weeks
  • Ongoing absorbable antibiotic use
  • ASA Class IV or V
  • Pregnant or nursing patients
  • Immunosuppression

Where in United States

  • Hunter Holmes McGuire VA Medical CenterRichmond, United States
  • Virginia Commonwealth UniversityRichmond, United States

About the trial

What the trial wants to find out

The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.

The 2 groups in the trial

  • Intestinal Microbiota Transplant capsulesTreatment being tested

    Capsules will be provided twice during the trial

    Treatment: Intestinal Microbiota Transplant (IMT) Capsules

  • Placebo capsulesPlacebo, for comparison

    Capsules will be provided twice during the trial

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Record updated
24 August 2026